USPh

ONE PARTNER

Investor Presentation

March 8, 2021

Forward Looking Statements

This presentation contains forward-looking statements, which involve numerous risks and uncertainties. Included are statements relating to opening of new clinics, availability of personnel and reimbursement environment. The forward-looking statements are based on the Company's current views and assumptions and the Company's actual results could differ materially from those anticipated as a result of certain risks, uncertainties, and factors, which include, but are not limited to: general economic, business, and regulatory conditions; public health crises and epidemics/pandemics, such as the novel strain of COVID-19; competition; reimbursement conditions; federal and state regulation; acquisitions; clinic closures, availability, terms, and use of capital; availability and cost of skilled physical and occupational therapists; and weather. See Risk Factors in Item 1A of our Annual Report of Form 10-K for the year ended December 31, 2020.

Investment Highlights

Established Company	• 553 outpatient physical and occupational therapy clinics across 39 states • One of the largest owner/operator of PT clinics • Only publicly-traded, pure play provider
Attractive Market Dynamics	• US rehab market > $30B in annual revenue • Highly fragmented; No company with >10% market share • Favorable demographics – aging and active population
Proven Business Model	• Partner with experienced physical therapists • Driven by organic growth and acquisitions • Approximately one-half of clinics were de novo start-ups
Solid Financial Position	• Strong cash flow and balance sheet • Diversified payor mix, 32% of net patient revenue from Medicare and Medicaid

Focused Business Model

- Specialize in trauma, sports, work-related and pre and post surgical cases
- Partner with experienced physical therapists
  - Drive volume via referrals
  - Augment sales with marketing reps
- Historical focus on organic growth via lower cost de novo (start-up) clinics
- Strategic acquisitions structured like de novos as partnerships with significant ownership retained by founders

USPh ONE PARTNER

Large and Growing Market Opportunity

- $30B+ U.S. rehab market with projected growth
- Favorable demographics – physically active, aging and obese population segments
- Untapped market potential – each year ~50% of Americans over the age of 18 develop a musculoskeletal injury that lasts more than 3 months; only 10% use outpatient physical therapy services[1]
- Healthcare delivery shifting towards lower cost, high quality outpatient providers

(1) Source: "Industry Trends in M&A and Total Addressable Market Study" (Bain & Company, WebPT)

USPh ONE PARTNER

Setting for Physical Therapy Care



- Orthopedic rehab is the primary driver of physical therapy services, representing approximately 60% of visits

Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT)

Payers See Significant ROI for Physical Therapy



Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT)

Competitive Landscape

- Highly fragmented U.S. outpatient rehab market with 37,000 + clinics[1]
- No company with >10% market share
- USPh is one of the largest owner/operator of PT clinics
  - Select Medical/Physio 1740 Clinics
  - ATI 894 Clinics
  - USPh 553 Clinics

[1]Source: "Industry Trends in M&A and Total Addressable Market Study" (Bain & Company, WebPT)

Growth Strategy

Drive organic growth through de novo PT/OT clinic openings, utilize true partnership model

Maximize profits of existing facilities by growing patient volume, improving pricing and increasing efficiencies

Augment organic growth through strategic acquisitions

USPH Partnership Advantages

Less Administrative Burden

- ✓ Accounting
- ✓ HR
- ✓ Real Estate
- ✓ Construction
- ✓ Purchasing
- ✓ Marketing
- ✓ Compliance
- ✓ Legal
- ✓ IT

More Resources

- ✓ Access to Capital for Development of Additional Clinics
- ✓ Less Personal Financial Risk
- ✓ Unlimited Earnings Potential
- ✓ Full Benefit Package
- ✓ Ongoing Guidance within Semi-Autonomous Work Environment

National Footprint



553 Clinics in 39 States as of February 28, 2021

Acquisition Strategy

- Completed 36 acquisitions since 2005
- Range in size from 3 to 52 clinics
- Acquisition criteria:
  - ✓ Owner therapists continue to operate clinics and retain significant equity interest
  - ✓ Immediately accretive to earnings
  - ✓ Further de novo growth opportunities

Scale Advantages Create a Robust Business Case for Consolidation

- Increased likelihood of selection for payer networks
  - ➢ Scale is cited as a core criterion by specialty network managers and payers.
  - ➢ Some limited leverage in negotiations with payers for reimbursement
- Higher likelihood of referrer activity and advocacy
- More efficient, patient-centric care model -- including clinic, home and telehealth options
- Enhanced compliance capabilities
- Centralized infrastructure to limit costs and improve operational efficiencies
- Increased patient awareness and high brand recognition

Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT)

New Clinics / Brands 2021

2020 Through 02/28/2021



553 Clinics in 39 States as of February 28, 2021

USPh ONE PARTNER

Executive Management

- **Chris Reading – Chief Executive Officer**
  - Joined USPh as COO in November 2003
  - Promoted to CEO and Board in November 2004
  - Previously Senior Vice President of Operations with HealthSouth, managed over 200 facilities including OP, ASC, DX Imaging and rehab hospital operations.
  - BS Physical Therapy
- **Carey Hendrickson – Chief Financial Officer**
  - Joined USPh as CFO in November 2020
  - Previously served as CFO for Capital Senior Living Corporation **(NYSE:CSU)** and Belo Corp**. (NYSE: BLC)**
  - BBA & MBA
- **Glenn McDowell – Chief Operating Officer – Central/West Regions**
  - Joined USPh as Vice President - West Region in October 2003
  - Promoted to COO in January 2005
  - Previously Vice President of Operations with HealthSouth, managed 165 facilities including ASC, DX Imaging, OP and occupational medicine facilities.
  - BS & Masters Physical Therapy
- **Graham Reeve – Chief Operating Officer – East Region**
  - Joined USPh in March 2018
  - Previously President & Chief Executive Officer of Baptist Health System in San Antonio, TX. Managed six hospitals with a $1.32B annual operating budget.
  - BS Physical Therapy & MBA

USPH Physical Therapy Net Revenue Mix



Industrial Injury Prevention & Worker's Comp

- Both internally and through acquisition, USPh has expanded its industry-focused Industrial Injury Prevention and Worker's Comp business.
- In March 2017, April 2018 and April 2019 USPh acquired leading providers of Industrial Injury Prevention services.
- Industrial Injury Prevention (Briotix Health) services include rehabilitation, performance optimization and ergonomic assessments. Services are performed onsite at more than 600 client locations.
- Worker's Comp (Fit2WRK) Services provided in our physical therapy clinics include job specific rehabilitation, work hardening/conditioning, post-offer pre-employment screening and functional capacity evaluations ("FCE"). National approach with local care delivery, 1-800-centralized scheduling-fast, easy and convenient.
- Industrial Injury Prevention and Worker's Comp combined accounted for 21% of USPH's total revenue for the year ended December 31, 2020.

USPH Total Revenue



USPH Physical Therapy Growth Drivers

Prior to Covid-19 pandemic each driver showed robust growth historically







*In 2019, the Company's interest in a partnership was sold, which operated 30 clinics. In 2020, the Company sold 14 previously closed clinics and closed 34 clinics.

USPH Physical Therapy Clinic Level Margin



* Quarterly margins in 2020: 1Q 17.3%, 2Q 21.7%, 3Q 28.0%, 4Q 24.9%

Industrial Injury Prevention





Dividend

- The Company initiated a quarterly dividend in 2011, and subsequently increased the quarterly dividend rate each year.
- Temporarily suspended quarterly dividend after Q1 2020 due to uncertainty associated with Covid-19 pandemic
- Reinstated the quarterly dividend in Q1 2021 at $0.35 per share, an increase of 9.4% from previous dividend paid
- Dividend seen as an additional way to increase returns to shareholders as Company is under-leveraged and has excellent net free cash flow
- Dividends do not impact our ability to continue to grow internally through de novo clinic development and externally through acquisitions

COVID-19

- With the March onset of the pandemic, the Company took a number of actions to preserve cash and mitigate losses including staffing adjustments and clinic closures
- Initially, 70 out of 585 clinics were closed (30 temporarily and 40 permanently) based on the presumption of lower patient volumes for a sustained period of time. All temporarily closed clinics have reopened. In 2020, we closed a total of 48 clinics, of which 14 were sold.
- The Company reduced its workforce from 5,500 to 3,200 at the onset of the pandemic through furloughs and a reduction-in-force. Approximately 1,200 furloughed employees have returned to work on a full or part-time basis as patient volumes have increased.
- Salary reductions were also implemented for Corporate support personnel and certain operational leadership roles, including 35% to 40% reductions for executives.

COVID-19 RECOVERY



- In April 2020, patient volumes were approximately 45% of pre-COVID volumes. Volumes grew consistently from May through December 2020.
- The Company's industrial injury prevention (IIP) business has been less affected by the pandemic and is currently running at slightly less than it's pre-COVID levels. IIP revenues increased $1.7 million, or 4.6%, in 2020 as compared to 2019, inclusive of an acquisition in April 2019.

Strong Cash Flow and Balance Sheet

- At December 31, 2020, we had $32.9 million in cash and $16.0 million outstanding on our line of credit. Included in cash are $14.1 million of MAAPP funds and $8.3 million in deferred payroll taxes.
- Both de novo clinics and acquisitions financed primarily through free cash flow.
- In 2020, the Company generated Adjusted EBITDA[(1)] of $70.0 million inclusive of Relief Funds (without Relief Funds = $56.5 million).

(1) Adjusted EBITDA is defined as net income contributable to USPh shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and, derecognition of goodwill due to certain clinic closures.

Strong Return to Shareholders



*** CEO and COO-West joined Company in Fall of 2003; COO-East in Spring of 2018; and CFO in Fall of 2020.**

Total Cumulative Return through December, 2020 including dividends is $114.46.

Total Cumulative Return Percentage is 937.4%

Average Annual Return is 54.3%

Market Cap increase during time period is from $154.7 million to $1.5 billion or by $1.4 billion (899%)

Full Year 2020 Results

	Year Ended December 31, 2020	Year Ended December 31, 2019
Revenue	$ 423.0 M	$ 482.0 M
Gross Margin	$ 94.5 M	$ 112.5 M
Operating Income	$ 52.4 M	$ 67.4 M
Net Income (GAAP)	$ 35.2 M	$ 40.0 M
Operating Results (w/o Relief Funds)	$ 30.6 M	$ 36.0 M
Operating Results (w/Relief Funds)	$ 38.4 M	$ 36.0 M
EPS (Operating Results w/o Relief Funds)	$ 2.39	$ 2.82
EPS (Operating Results w/Relief Funds)	$ 2.99	$ 2.82
EPS (GAAP)	$ 2.48	$ 2.45
Adjusted EBITDA (w/o Relief Funds)	$ 56.5 M	$ 72.8 M
Adjusted EBITDA (w/Relief Funds)	$ 70.0 M	$ 72.8 M

*Operating Results, a non-Generally Accepted Accounting Principles ("GAAP") measure, equals net income attributable to USPH shareholders per the consolidated statements of net income plus charges incurred for closure costs, less gain on the sale of partnership interests and clinics, less allocated non-controlling interests, excludes expenses incurred for the CFO recruitment and charges related to the acceleration of CFO restricted stock, all net of tax.

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and write-off of goodwill related to certain clinic closures.

USPh ONE PARTNER

Fourth Quarter 2020 Results

	Three Months Ended	
	December 31, 2020	December 31, 2019
Revenue	$ 117.5 M	$ 122.1 M
Gross Margin	$ 29.1 M	$ 27.0 M
Operating Income	$ 18.2 M	$ 15.3 M
Net Income (GAAP)	$ 13.0 M	$ 7.9 M
Operating Results (without relief funds)	$ 10.9 M	$ 8.2 M
Operating Results (with relief funds)	$ 13.9 M	$ 8.2 M
EPS (Operating Results without relief funds)	$ 0.85	$ 0.64
EPS (Operating Results with relief funds)	$ 1.08	$ 0.64
EPS (GAAP)	$ 0.68	$ 0.55
Adjusted EBITDA (without relief funds)	$ 18.3 M	$ 15.3 M
Adjusted EBITDA (with relief funds)	$ 23.5 M	$ 15.3 M

*Operating Results, a non-Generally Accepted Accounting Principles ("GAAP") measure, equals net income attributable to USPH shareholders per the consolidated statements of net income plus charges incurred for closure costs, less gain on the sale of partnership interests and clinics, less allocated non-controlling interests, excludes expenses incurred for the CFO recruitment and charges related to the acceleration of CFO restricted stock, all net of tax.

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and write-off of goodwill related to certain clinic closures.

USPh ONE PARTNER

Summary

Only publicly-traded, pure play operator of rehab clinics

Proven business model, driven by organic growth and acquisitions

Significant scale with national footprint

Large and growing market/favorable demographics

Strong cash flow and balance sheet

Reconciliation of Non-GAAP Financial Measures – Adjusted EBITDA

	Year Ended December 31, (amounts in 000's)	
	2020	**2019**
Net Revenues	$ 422,969	$ 481,969
Net Income Attributable to USPh	$ 35,194	$ 40,039
Depreciation and Amortization	$ 10,533	$ 10,095
Relief Funds	$ (13,500)	$ -
Interest Income	$ (142)	$ (46)
Closure Costs – write off goodwill	$ 1,859	$ -
Interest expense – debt and other	$ 1,634	$ 2,079
Equity grant expense	$ 13,022	$ 13,647
Provision for Income Taxes	$ 7,917	$ 6,985
Adjusted EBITDA (without Relief Funds)	$ 56,517	$ 72,799
Relief Funds	$ 13,500	$ -
Adjusted EBITDA (with Relief Funds)	$ 70,017	$ 72,799

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and write-off of goodwill related to certain clinic closures.

USPh ONE PARTNER

Reconciliation of Non-GAAP Financial Measures – Adjusted EBITDA

	Three Months Ended December 31, (amounts in 000's)	
	2020	**2019**
Net revenues	$ 117,466	$122,114
Net Income attributable to USPH	$ 13,030	$ 7,929
Depreciation and amortization	$ 2,654	$ 2,718
Relief Funds	$ (5,151)	$ -
Interest income	$ (45)	$ (19)
Closure cost – write-off of goodwill	$ -	$ -
Interest expense – debt and other	$ 203	$ 557
Equity grant expense	$ 2,592	$ 1,723
Provision for income taxes	$ 5,023	$ 2,424
Adjusted EBITDA (without relief funds)	$ 18,306	$ 15,332
Relief Funds	$ 5,151	$ -
Adjusted EBITDA (with relief funds)	$ 23,457	$ 15,332

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and write-off of goodwill related to certain clinic closures.

Reconciliation of Non-GAAP Financial Measures – Operating Results

Computation of earnings per share – USPH shareholders:	Year Ended December 31, (in 000's, except per share data) 2020	2019
Net Income attributable to USPh Shareholders	$ 35,194	$ 40,039
Charges (credits) to retained earnings:		
Revaluation of redeemable non-controlling interests	$ (4,632)	(11,893)
Tax effect at statutory rate (federal and state) of 26.25%	$ 1,216	3,121
	$ 31,778	$ 31,267
Earnings per share (basic and diluted)	$ 2.48	$ 2.45
Adjustments:		
Charges related to CFO transsition	$ 1,331	$ -
Closure Costs	$ 3,931	$ -
Gain on sale of partnership interest and clinics	$ (1,091)	$ (5,514)
Relief funds	$ (13,500)	$ -
Allocation to non-controlling interest	$ 3,116	$ -
Revaluation of redeemable non-controlling interest	$ 4,632	$ 11,893
Tax effect at statutory rate (federal and state) of 26.25%	$ 415	$ (1,674)
Operating results (without relief funds)	$ 30,612	$ 35,972
Relief Funds	$ 13,500	$ -
Allocation to non-controlling interest	$ (2,893)	$ -
Tax effect at statutory rate (federal and state) of 26.25%	$ (2,784)	$ -
	$ 38,435	$ 35,972
Basic and diluted operating results (without relief funds) per share	$ 2.39	$ 2.82
Basic and diluted operating results (with relief funds) per share	$ 2.99	$ 2.82
Shares used in computation	$ 12,835	$ 12,756

*Operating Results, a non-Generally Accepted Accounting Principles ("GAAP") measure, equals net income attributable to USPH shareholders per the consolidated statements of net income plus charges incurred for closure costs, less gain on the sale of partnership interests and clinics, less allocated non-controlling interests, excludes expenses incurred for the CFO recruitment and charges related to the acceleration of CFO restricted stock, all net of tax.

USPh ONE PARTNER

Reconciliation of Non-GAAP Financial Measures – Operating Results

	Three Months Ended December 31, (in 000's except per share data)	
Computation of earnings per share – USPH shareholders:	**2020**	**2019**
Net Income attributable to USPh Shareholders	$ 13,030	$ 7,929
Charges (credits) to retained earnings:		
Revaluation of redeemable non-controlling interest	$ (5,807)	$ (1,141)
Tax effect at statutory rate (federal and state) of 26.25%	$ 1,524	$ 299
	$ 8,747	$ 7,087
Earnings per share (basic and diluted)	$ 0.68	$ 0.55
Adjustments:		
Expenses related to CFO transition	$ 1,129	$ -
Closure Costs	$ 6	$ -
Adjustment on sale of partnership interest and clinics	$ -	$ 309
Relief Fund	$ (5,151)	$ -
Allocation to non-controlling interest	$ 1,139	$ -
Revaluation of redeemable non-controlling interest	$ 5,807	$ 1,141
Tax effect at statutory rate (federal and state) of 26.25%	$ (769)	$ (380)
Operating results (without relief funds)	$ 10,908	$ 8,157
Relief funds	$ 5,151	-
Allocation to non-controlling interest	$ (1,140)	
Tax effect at statutory rate (federal & state) of 26.25%	$ (1,053)	$ -
	$ 13,866	$ 8,157
Basic and diluted operating results (without relief funds) per share	$ 0.85	$ 0.64
Basic and diluted operating results per share (with relief funds)	$ 1.08	$ 0.64
Shares used in computation	$ 12,851	$ 12,774

*Operating Results, a non-Generally Accepted Accounting Principles ("GAAP") measure, equals net income attributable to USPH shareholders per the consolidated statements of net income plus charges incurred for closure costs, less gain on the sale of partnership interests and clinics, less allocated non-controlling interests, excludes expenses incurred for the CFO recruitment and charges related to the acceleration of CFO restricted stock, all net of tax

USPh ONE PARTNER

USPh

ONE PARTNER